Literature DB >> 15362741

Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas.

Mee Sook Roh1, Jin Sook Jeong, Young Hoon Kim, Min Chan Kim, Sook Hee Hong.   

Abstract

BACKGROUND/AIMS: Malignant cells require high energy via glycolytic generation of ATP for cell proliferation and survival. This process is thought to be mediated by glucose transporters (GLUTs). GLUT1 appears to be expressed aberrantly in many cancers. The liver is the main organ closely related to glycogen metabolism and it is thought that GLUT expression might be altered in the tumors arising in the liver.
METHODOLOGY: We studied GLUT1 expression in 22 hepatocellular carcinomas (HCC) and 16 cholangiocarcinomas (CC) and compared it to the expression of hepatocyte specific antigen (HSA) and cytokeratin 19 (CK19) by immunohistochemical studies.
RESULTS: In HCC, GLUT1 was expressed in 4.5% (1/22), HSA in 77.3% (17/22) and CK19 in none (0/22). In CC, GLUT1 was expressed in 81.3% (13/16), HSA in none (0/16) and CK19 in 100% (16/16). Interestingly, GLUT1 was not expressed in normal hepatocytes and bile duct epithelium around the tumor, whereas CK19 was expressed in normal bile ducts and tumor cells.
CONCLUSIONS: These results indicate that GLUT1 might be related to development of bile duct carcinoma and its expression was a more reliable marker for detection of bile duct carcinoma than CK19. Additionally, GLUT1 might potentially be useful as a means of distinguishing CC from HCC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15362741

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

Review 1.  Hepatic expression and cellular distribution of the glucose transporter family.

Authors:  Sumera Karim; David H Adams; Patricia F Lalor
Journal:  World J Gastroenterol       Date:  2012-12-14       Impact factor: 5.742

Review 2.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

3.  Functional properties and genomics of glucose transporters.

Authors:  Feng-Qi Zhao; Aileen F Keating
Journal:  Curr Genomics       Date:  2007-04       Impact factor: 2.236

4.  GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis.

Authors:  Thomas Amann; Ulrike Maegdefrau; Arndt Hartmann; Abbas Agaimy; Jörg Marienhagen; Thomas S Weiss; Oliver Stoeltzing; Christina Warnecke; Jürgen Schölmerich; Peter J Oefner; Marina Kreutz; Anja K Bosserhoff; Claus Hellerbrand
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

Review 5.  Plasma Membrane Transporters as Biomarkers and Molecular Targets in Cholangiocarcinoma.

Authors:  Jose J G Marin; Rocio I R Macias; Candela Cives-Losada; Ana Peleteiro-Vigil; Elisa Herraez; Elisa Lozano
Journal:  Cells       Date:  2020-02-21       Impact factor: 6.600

6.  Glucose transporters as markers of diagnosis and prognosis in cancer diseases.

Authors:  Leszek Szablewski
Journal:  Oncol Rev       Date:  2022-02-22

Review 7.  Clinical application of 18F-fluorodeoxyglucose positron emission tomography for assessment and evaluation after therapy for malignant hepatic tumor.

Authors:  Masakatsu Tsurusaki; Masahiko Okada; Hiroyuki Kuroda; Mitsuru Matsuki; Kazunari Ishii; Takamichi Murakami
Journal:  J Gastroenterol       Date:  2013-03-26       Impact factor: 7.527

8.  Quantitative assessment of simultaneous F-18 FDG PET/MRI in patients with various types of hepatic tumors: Correlation between glucose metabolism and apparent diffusion coefficient.

Authors:  Eunjung Kong; Kyung Ah Chun; Ihn Ho Cho
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.